New Corporate Presentation

N4 Pharma PLC

11 June 2024

 

N4 Pharma plc

 ("N4 Pharma" or the "Company")

New Corporate Presentation

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to announce that a new Corporate Presentation has been published.  

The Corporate Presentation can be viewed on the Company's interactive investor hub, at: https://investors.n4pharma.com/activity-updates/n4-pharma-company-presentation-june-24

For more information please contact:

N4 Pharma plc Nigel Theobald, CEO Luke Cairns, Executive Director	investors.n4pharma.com
SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Matthew Johnson/Caroline Rowe/Kasia Brzozowska (Corporate Finance) Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)	Tel: [phone]
Turner Pope Investments (TPI) Limited Joint Broker Andy Thacker James Pope	Tel: [phone]
InvestorHub Engage with us by asking questions, watching video summaries and seeing what other shareholders have to say.	https://investors.n4pharma.com/link/YeNdZP

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for oncology, gene therapy and vaccines using its unique silica nanoparticle delivery system called Nuvec®.

N4 Pharma's business model is to partner with companies developing novel antigens in these fields to use Nuvec® as the delivery vehicle for these antigens. As these products progress through pre‐clinical and clinical programs, N4 Pharma will seek to receive upfront payments, milestone payments and ultimately royalty payments once products reach the market.

For further information on the Company visit www.n4pharma.com or sign up at https://investors.n4pharma.com/auth/signup.

 

END